Seaport Therapeutics (SPTX) News
NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.05-0.27 (-1.47%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPTX news summary
We found 4 recent headlines mentioning Seaport Therapeutics (SPTX): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, SPTX is down 1.47% at $18.05. The most recent story, "Seaport Therapeutics Reports Positive GlyphAllo Data; GlyphAgo Phase 2a Trial Underway", was published by Nasdaq on Nov 2, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Seaport Therapeutics headlines
- Seaport Therapeutics Reports Positive GlyphAllo Data; GlyphAgo Phase 2a Trial Underway(RTTNews) - Seaport Therapeutics, Inc. (SPTX) reported third-quarter 2026 financial results and highlighted clinical progress across its neuropsychiatric pipeline. The company announced positive…NasdaqSPTX, SUN
- Seaport Therapeutics, Inc. GAAP EPS of -$0.49 beats by $0.09Seeking Alpha
- Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressBOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressBusiness Wire
- Canaccord Genuity Initiates Coverage of Seaport Therapeutics with Buy RatingFintel reports that on October 14, 2026, Canaccord Genuity initiated coverage of Seaport Therapeutics (NASDAQGS:SPTX) with a Buy recommendation.Prior to this coverage initiation, the stock closed at…Nasdaq